Uveal Melanoma

Overview

Journal J Skin Cancer

Publisher Wiley

Specialty Dermatology

Date 2011 Jul 21

PMID 21773036

Citations 20

Authors

Vasilios P Papastefanou

Victoria M L Cohen

Affiliations

Soon will be listed here.

Abstract

Uveal melanoma is the most common primary intraocular malignancy and the leading primary intraocular disease which can be fatal in adults. In this paper epidemiologic, pathogenetic, and clinical aspects of uveal melanoma are discussed. Despite the advance in local ocular treatments, there has been no change in patient survival for three decades. Development of metastases affects prognosis significantly. Current survival rates, factors predictive of metastatic potential and metastatic screening algorithms are discussed. Proposed and emerging treatments for uveal melanoma metastases are also overviewed. Current advances in genetics and cytogenetics have provided a significant insight in tumours with high metastatic potential and the molecular mechanisms that underlie their development. Biopsy of those lesions may prove to be important for prognostication and to allow further research into genetic mutations and potential new therapeutic targets in the future.

Citing Articles

Femtosecond pulsed laser photodynamic therapy activates melanin and eradicates malignant melanoma.

Pires L, Khattak S, Pratavieira S, Calcada C, Romano R, Yucel Y Proc Natl Acad Sci U S A. 2024; 121(14):e2316303121.

PMID: 38551838 PMC: 10998568. DOI: 10.1073/pnas.2316303121.

Light Pollution and Oxidative Stress: Effects on Retina and Human Health.

Salceda R Antioxidants (Basel). 2024; 13(3).

PMID: 38539895 PMC: 10968061. DOI: 10.3390/antiox13030362.

Protective Effect of Curcuma Extract in an Model of Retinal Degeneration via Antioxidant Activity and Targeting the SUMOylation.

Hassanzadeh K, Vahabzadeh Z, Bucarello L, Dragotto J, Corbo M, Maccarone R Oxid Med Cell Longev. 2022; 2022:8923615.

PMID: 35941902 PMC: 9356244. DOI: 10.1155/2022/8923615.

Clinicopathologic features and survival outcomes of ocular melanoma: a series of 31 cases from a tertiary university hospital.

Kestel S, Uyar Gocun F, Ogut B, Erdem O J Pathol Transl Med. 2022; 56(4):187-198.

PMID: 35501671 PMC: 9288897. DOI: 10.4132/jptm.2022.03.10.

The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival.

Dewaele S, Delhaye L, De Paepe B, de Bony E, De Wilde J, Vanderheyden K Oncogene. 2021; 41(1):15-25.

PMID: 34508176 PMC: 8724009. DOI: 10.1038/s41388-021-02006-x.

References

Klingenstein A, Haug A, Nentwich M, Tiling R, Schaller U . Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma. Melanoma Res. 2010; 20(6):511-6. DOI: 10.1097/CMR.0b013e3283403d6c. View

Diener-West M, Hawkins B, Markowitz J, Schachat A . A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol. 1992; 110(2):245-50. DOI: 10.1001/archopht.1992.01080140101036. View

Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel K, Becher R . Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996; 347(9010):1222-5. DOI: 10.1016/s0140-6736(96)90736-9. View

Missotten G, Notting I, Schlingemann R, Zijlmans H, Lau C, Eilers P . Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol. 2006; 124(10):1428-34. DOI: 10.1001/archopht.124.10.1428. View

Laver N, McLaughlin M, Duker J . Ocular melanoma. Arch Pathol Lab Med. 2010; 134(12):1778-84. DOI: 10.5858/2009-0441-RAR.1. View

Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B . Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2002; 43(8):2579-83. View

Gunduz K, Shields C, Shields J, Cater J, Freire J, BRADY L . Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol. 1999; 117(5):609-14. DOI: 10.1001/archopht.117.5.609. View

Singh A, Topham A . Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003; 110(5):956-61. DOI: 10.1016/S0161-6420(03)00078-2. View

Bauer J, Kilic E, Vaarwater J, Bastian B, Garbe C, de Klein A . Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer. 2009; 101(5):813-5. PMC: 2736834. DOI: 10.1038/sj.bjc.6605226. View

10.

Shields C, Shields J, Kiratli H, De Potter P, Cater J . Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995; 102(9):1351-61. View

11.

Damato B, Duke C, Coupland S, Hiscott P, Smith P, Campbell I . Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007; 114(10):1925-31. DOI: 10.1016/j.ophtha.2007.06.012. View

12.

Ehlers J, Worley L, Onken M, Harbour J . Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res. 2008; 14(1):115-22. DOI: 10.1158/1078-0432.CCR-07-1825. View

13.

Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E . Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12):2309-15. DOI: 10.1016/j.ophtha.2007.01.032. View

14.

Shildkrot Y, Wilson M . Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. Curr Opin Ophthalmol. 2009; 20(6):504-10. DOI: 10.1097/ICU.0b013e328330b549. View

15.

Shields C, Ganguly A, Bianciotto C, Turaka K, Tavallali A, Shields J . Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology. 2010; 118(2):396-401. DOI: 10.1016/j.ophtha.2010.05.023. View

16.

Bedikian A, Legha S, Mavligit G, Carrasco C, Khorana S, Plager C . Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995; 76(9):1665-70. DOI: 10.1002/1097-0142(19951101)76:9<1665::aid-cncr2820760925>3.0.co;2-j. View

17.

Robertson D . TTT as rescue treatment for choroidal melanoma not controlled with iodine-125 brachytherapy. Ocul Immunol Inflamm. 2003; 10(4):247-52. DOI: 10.1076/ocii.10.4.247.15587. View

18.

Economou M, All-Ericsson C, Bykov V, Girnita L, Bartolazzi A, Larsson O . Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci. 2005; 46(12):4372-5. DOI: 10.1167/iovs.05-0322. View

19.

Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T . Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9. PMC: 3107972. DOI: 10.1056/NEJMoa1000584. View

20.

Brantley Jr M, Harbour J . Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000; 157(6):1795-801. PMC: 1885790. DOI: 10.1016/s0002-9440(10)64817-1. View